HIGHLIGHTS
- who: M. Nadjafi md and collaborators from the guidelines recommend the routine use of ihc in biopsy samples when accurate subtyping cannot be performed based on morphologic assessment A final diagnosis of nsclc not otherwise specified (nos) has been associated with an unfavourable prognosis in patients with stage iv nsclc and should be refined wherever possible24. Precise histologic characterization of nsclc has become essential for therapeutic decision-making because the results can predict response to various systemic treatments25, . With the development of novel therapies and diagnostic techniques, shifts have occurred over time in the use of various . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.